Protein Expression Market Size, Share, Trends, Growth, Forecast 2022-2030

The global Protein Expression market size is expected to hit around US$ 13.0 billion by 2030, according to a new report by Vision Research Reports.

The global Protein Expression market size was valued at US$ 11.2 billion in 2020 and is anticipated to grow at a CAGR of 20.4% during forecast period 2021 to 2030.

Report Highlights

  • The prokaryotic segment held the largest share of over 40.04% in 2021.
  • Reagents dominated the market with a revenue share of over 40.03% in 2021.
  • The services segment is anticipated to expand at a CAGR of 12.5% from 2022 to 2030.
  • The therapeutic segment dominated the market with over 50.07% in 2021 and is anticipated to register the highest growth rate over the forecast period.
  • The pharmaceutical and biotechnological companies segment held the largest revenue share of over 45.3% in 2021.
  • North America dominated the regional market with a share of over 40.23% in 2021.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37931

Growth Factors

The growing demand for biologics and expansion of the biopharmaceutical industry have resulted in massive growth of the protein expression market. Rising demand for therapeutic proteins such as insulin, hormones, monoclonal antibodies,and vaccines is a major factor that propels growth of the market during forecast period. Thus, many biotechnology and pharmaceuticals companies have begun to concentrate on the development and manufacturing of advanced therapeutic proteins for the treatment of severe chronic diseases such as cancer, hemophilia, infectious diseases, anemia, and multiple sclerosis.

Increasing investment in the R&D, by biotechnology and pharmaceutical companies, is another major factor supporting the sector growth. The availability of new and advanced technologies to cater the needs of drugs & biologics product manufacturers boosts the adoption of protein expression products for research and manufacturing applications. In addition, several pharmaceutical and biotechnology manufacturers are undergoing collaborations and partnerships to achieve leadership in the sector. For instance, in December 2016, Takara Bio, Inc. signed a merger agreement with Rubicon Genomics, Inc. to strengthen its genomics business.

Scope of The Report

Report Coverage

Details

Market Size in 2020

USD 11.2 billion
 

Revenue Forecast by 2030

USD 13.0 billion

Growth rate from 2021 to 2030

CAGR of 20.4%
 

Base Year

2020

Forecast Period

2021 to 2030

Segmentation

Expression Systems, Product, Application, End-use, Region
 

Companies Covered

Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Merck KGaA, Promega Corporation, New England Biolabs, Qiagen, and Takara Bio, Inc. share market with local vendors.

 

Key Market Trends

Cell-free Expression is Expected to Hold a Major Market Share in the Protein Expression Market

The cell-free protein expression is well-established in the market, due to its acceptance, and this protein expression is performed without the use of living cells. This technique has many advantages over other protein expression techniques and because of its advantages, it is widely used. Due to the advantages of cell-free protein techniques, such as increased speed, ability to express toxic proteins, ease of amino acid type selective labeling, among others, these are making the cell expression market grow.

Furthermore, the growing launches of cell-free systems boost the usage of the kits and reagents. For instance, in 2019, Arbor Biosciences announced the launch of myTXTLTM bulk offerings of cell-free expression systems. These new offerings align with the growing demand for larger volume requirements by organizations utilizing high-throughput screening in protein and enzyme engineering. These cell-free expression systems are currently available from Arbor Biosciences as a Sigma 70 or a linear DNA expression master mix.

Moreover, the growing research and studies on cell-free systems, especially due to COVID is further boosting the growth of the segment. In the article ‘Combating COVID-19 with Cell-Free Expression’ published in October 2020, synthetic biologists pivoted the cell-free expression technology that they were using for other diseases to develop new diagnostics, materials, and treatments specifically for COVID-19.

Therefore, the unique technology may increase the growth of the cell-free expression market, which in turn, is expected to boost the protein expression market.

Expression System Insights

The prokaryotic segment held the largest share of over 40.04% in 2021 as it is relatively easier to handle and fulfill major purposes in research. The segment is anticipated to maintain its position in the forecast period owing to favorable characteristics, such as large-scale recombinant protein production in a short time and at a lower cost.

The mammalian cell segment is projected to grow at the fastest rate during the forecast period. Various pharmaceutical companies have employed mammalian expression systems to develop and produce proteins transiently or through stable cell lines. This takes place where particular expression constructs combine into the genome host. However, the employment of systems depends on the purpose and approach. For instance, for antigen production, structural studies, and activity studies, wherein post-translational is not a requirement, the prokaryotic is considered to be ideal. However, companies prefer mammalian cells for the production of vaccines, therapeutics, and proteins.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37931

Product Insights

Reagents dominated the market with a revenue share of over 40.03% in 2021. The market consists of mature players such as Agilent Technologies, Inc. and Thermo Fisher Scientific. The companies offer a wide range of transfection reagents to fulfill the particular needs of transfection and idealize the conditions of cell culture. 

The services segment is anticipated to expand at a CAGR of 12.5% from 2022 to 2030. The growth is attributed to the increasing outsourcing by pharmaceutical and biotech companies to antibody production companies for protein production and expression to support their personalized assay development and discovery of therapeutic antibodies.

Similarly, numerous players are employing strategic initiatives to expand their presence in the market. In August 2022, BioIVT announced the acquisition of Cypex, as the acquired company’s product range of proteins complements BioIVT’s solutions for drug research and development. Furthermore, Cypex’s offerings are developed through patented technology, that allows the expression of human drug-metabolizing enzymes in bacteria, without the need for a major modification to the proteins.

Application Insights

The therapeutic segment dominated the market with over 50.07% in 2021 and is anticipated to register the highest growth rate over the forecast period as protein therapeutics pose numerous advantages over other medications. They are customizable, resulting in a more effective line of treatment and a low probability of side effects. Additionally, it can act as a replacement treatment during the shortage of a functional protein in the body owing to gene deficiency.

The most important driver of this application segment is the increasing participation of companies in developing protein-based therapeutics as the approval time is comparatively shorter and has better patent protection regulation. Both these factors increase the profitability of the pharma and biotech companies and encourage further investment in R&D.

End-user Insights

The pharmaceutical and biotechnological companies segment held the largest revenue share of over 45.3% in 2021 due to the widespread use of cultured cells for the development of therapeutics and personalized medicines. As of 2019, over 170 recombinant proteins are used in medicine across the globe. The segment is driven by the increasing innovative use of proteins in the pharmaceutical industry. For creating a superior value in therapeutic and protein stability, the companies use existing proteins with genetic variants coupled with completely new protein designs.

Contract research organizations are expected to register the fastest growth rate over the forecast period. This can be attributed to the range of specialized services provided by the organizations to the pharma and biopharma companies at considerable pricing, thereby offering a competitive advantage over their competitors. For instance, Charles River Laboratories offers services ranging from construction design to automated protein purification. 

Regional Insights

North America dominated the regional market with a share of over 40.23% in 2021. This major proportion of share can be attributed to the presence of key players in the region, increasing fund flow in R&D, and strong pipelines of biosimilars. It has been observed that collaboration between companies and academic institutions is one of the key strategies employed in the North American region.

Asia Pacific is anticipated to be the fastest-growing region over the forecast period owing to the increasing adoption of protein expression in various applications, particularly in India and China. Additionally, the emerging focus on proteomics and genomics research and increasing initiatives by academic institutions for innovative development in protein therapeutics have offered lucrative growth opportunities to the Asia Pacific market throughout the forecast period.

Key Players

Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Merck KGaA, Promega Corporation, New England Biolabs, Qiagen, and Takara Bio, Inc. share market with local vendors.

Market Segmentation

  • Expression Systems Outlook 
    • Prokaryotic expression systems
    • Mammalian cell systems
    • Insect cell systems
    • Yeast systems
    • Other systems
  • Product Outlook
    • Reagents
    • Competent cells
    • Expression vectors
    • Services
    • Instruments
  • Application Outlook 
    • Therapeutic
    • Industrial
    • Research
  • End-use Outlook
    • Pharmaceutical and biotechnological companies
    • Academic research
    • Contract research organizations
    • Others
  • Regional Outlook
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • MEA

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37931

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/

 

Back to news